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Seoul 120-752, South Korea; Email: ejlee423@yuhs.ac)AbstractMedullary thyroid carcinoma (MTC) originates from parafolli-
cularCcells. Estrogen receptorb (ERb) expressionwas detected
in normal parafollicular C cells and MTCtumor tissue, but ERa
expression in MTC tumors still remains undetermined. The
appearance and loss of ERa or ERb expression has been known
to play a role in the development and progression of many
human cancers. We performed immunohistochemical studies of
ERa, ERb, and Ki67, a mitotic index, in 11 human MTC tissue
samples. ERa was detected in 10 cases (91%), and ERb
expression was observed in 8 cases (72.7%). A majority (8/10) of
ERa-positive tumors showing ERb Ki67 expression was
detected in three cases (27.3%). Neither clinical parameters
nor tumor node metastasis (TNM) tumor staging was correlated
with the positivity for ERs or Ki67. To investigate the biological
role of each ER, we used ER-negative MTC TT cells and
adenoviral vectors carrying ERa (Ad-ERa), ERb (Ad-ERb),Journal of Endocrinology (2007) 195, 255–263
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activator protein 1 (AP1)-Luc (Ad-AP1-Luc). Estrogen
stimulated and anti-estrogen, ICI 182 780, suppressed ERE
reporter activity in TT cells expressing ERa or ERb, suggesting
that both ERs use the same classical ERE-mediated pathway.
Ad-ERa infection stimulated TT cell growth; in contrast,
Ad-ERb infection suppressed their growth. Apoptosis was
detected in Ad-ERb-infected TT cells. Estrogen and anti-
estrogen suppressed AP1 activity in Ad-ERa-infected cells,
whereas upon Ad-ERb infection estrogen further stimulated
AP1 activity which in turn is suppressed by anti-estrogen,
suggesting that each ER acts differently through a non-ERE-
mediated pathway. Our results suggest that ERa and ERb may
play different roles in MTC tumor growth and progression.
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Medullary thyroid carcinoma (MTC), which comprises
3–10% of all carcinomas in the thyroid gland, may be either
sporadic or familial. Sex ratio is 1:1 with no difference
between sporadic and familial MTC (Kebebew et al. 2000a,b).
The familial form is part of the multiple endocrine neoplasia
type 2 (MENII) syndrome. MTC arises from the parafolli-
cular C cells of the thyroid gland. Metastases to distant sites
including lungs, liver, and bone usually occur early. There-
fore, any form of effective therapy with curative intent must
be systemic (Messina et al. 2000). The primary form of
treatment for MTC is total thyroidectomy, but recurrent and
metastatic diseases are difficult to manage. Although many
patients live with a recurrent or residual tumor for up to a
decade, the case fatality rate is ultimately 30–50% over 10years (Marsh et al. 1995). Because MTC responds poorly to
both chemotherapy and radiotherapy, targeted therapy
through cancer-specific signaling may offer an alternative
approach (Petrangolini et al. 2006).
Parafollicular C cells secrete a polypeptide hormone,
calcitonin. Previously, it has been demonstrated that calcitonin
gene expression is elevated in response to estrogen, suggesting
the presence of an estrogen receptor (ER; Naveh-Many et al.
1992). Immunohistochemical studies using monoclonal
antibody revealed that ERb, but not ERa, was detected in
normal human thyroid follicular and parafollicular C cells
(Taylor & Al-Azzawi 2000). More recently, a study showed that
ERb was expressed in most of the MTC tissues (Blechet et al.
2007).However, immunohistochemistry results (Bur et al. 1993,
Hiasa et al. 1993, Yane et al. 1993, Colomer et al. 1996,
Lewy-Trenda 2002, Arain et al. 2003, Blechet et al. 2007)DOI: 10.1677/JOE-06-0193
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follicular adenoma or carcinoma, papillary carcinoma,
medullary carcinoma, and anaplastic carcinoma remain
controversial depending on the antibody source.
Thyroid cancer is more prevalent in women than men,
and thyroid cancer incidence decreases after menopause
(Cady et al. 1979). These facts suggest a possible involvement
of estrogens in the carcinogenesis and progression of thyroid
cancer. Demonstration of ERa protein (Lee et al. 1998) and
ERa mRNA (Yane et al. 1994) in the normal and malignant
tissues of the thyroid seems to further support the hypothesis
that there is a direct action of estrogens on the thyroid tissues
and tumors. Estrogen has long been known to promote the
growth of certain human neoplasms, notably tumors of the
breast, endometrium, and pituitary. In contrast, ERb appears
to play a different role in carcinogenesis. Many reports have
shown that a loss of ERb expression is associated with the
progression of normal prostate epithelium into prostate
cancers (Latil et al. 2001, Leav et al. 2001, Fixemer et al.
2003). A similar down-regulation in ERb expression is also
noted in ovarian, breast, or colon tumors (Pujol et al. 1998,
Roger et al. 2001).
The expression of ERs or their biological role in the MTC
remains unclear. In this study, we investigated the ERs
expression in human MTC tissues and examined the role of
ERs using ER-negative MTC TT cells after expression of
ERs by adenoviral vectors.Materials and Methods
Subjects and immunohistochemistry of human MTC tumor
Eleven patients (five men and six women, mean age 48 years)
with MTC were included in this study. Ten patients had
sporadic MTC and one had MENIIa presenting as bilateral
MTC. The diagnosis of an MTC was established by the
measurement of serum calcitonin and carcino embryonic
antigen (CEA), and confirmed in all cases by positive
immunohistochemical staining of tumor tissue for calcitonin
(10 cases), CEA (11 cases), or chromogranin-A (10 cases).
One patient (case 5) with negative for calcitonin and
chromogranin-A had elevated serum CEA and immunohis-
tochemical positivity for CEA. Every MTC were poorly
differentiated under light microscopic examination. Meta-
static cervical lymph nodes were identified in seven patients
(63.6%) and distant metastasis occurred in two patients
(16.6%). The study design and protocol was approved by the
Internal Review Board of Severance Hospital, Yonsei
University College of Medicine.
To detect ERa or ERb in MTC tumors, 4 mm sections of
tumor in paraffin blocks were prepared. After deparaffinization,
slides were placed in a jar containing 10 mM sodium citrate
buffer (pH 6.0), exposed to microwave radiation (1000 W) for
15 min, and cooled to room temperature. After preincubation
with serum blocking solution, slides were incubated with mouseJournal of Endocrinology (2007) 195, 255–263monoclonal anti-human ERa (1:50, sc-8002, Santa Cruz
Biotechnology Inc., Santa Cruz, CA, USA specific to
C-terminal human ERa) or ERb (1:50, NCL-ERb, Novo-
Castra, specific to C-terminal human ERb) respectively,
overnight in a cold room. After washing with Tris-buffered
saline (TBS)/0.025% Tween, staining was performed by
biotinylated horse anti-mouse secondary antibodies (5 mg/ml,
Vector Laboratories, Burlingame, CA, USA), streptavidin-
horseradish peroxidase (RTU, Vector), and diamino benzidine
(DAB; DAKO). Theconcentrationof each antibody was titrated
using positive and negative control breast cancer tissues to
minimize non-specific staining. Counterstaining was per-
formed by malachite green. To investigate a possible correlation
of the presence of ERs with a cell proliferative index, Ki67
immunohistochemistry was also performed by mouse mono-
clonal antibody (1:50, DAKO, Fort Collins, CO, USA). Images
were obtained using a Zeiss microscope (Axioskop, Carl Zeiss
Inc., Oberkochen, Germany).Recombinant adenoviral vectors
Adenoviral vectors carrying the human ERa (Ad-ERa) and
ERb (Ad-ERb) were described previously (Cheng et al.
2004). E1-deleted adenoviral vector (Ad-E) was used as a
negative control. Adenoviral reporter vectors, Ad-3ERE-Luc
and Ad-AP1-Luc, were created to investigate transcriptional
activity of the ERa or ERb delivered by adenoviral vectors.
The sequence containing three consensus estrogen response
elements (3 ERE) and minimal TATA promoter was
generated by oligonucleotide annealing and ligated to the
pGL3-basic plasmid (Promega). A portion of the resulting
plasmid containing the upstream synthetic p(A) signal, 3
ERE, a minimal TATA promoter, the firefly luciferase gene,
and the downstream SV40 p(A) signal was subcloned into an
adenoviral transfer plasmid. The resulting plasmid,
pC-3ERE-Luc, was used to generate Ad-3ERE-Luc.
Similarly, Ad-AP1-Luc was generated from pC-AP1-Luc,
in which the sequence containing seven AP1 sites was
switched with three ERE sequences in pC-3ERE-Luc. The
sequences of the expression cassettes in the adenoviral vectors
were confirmed by automated DNA sequencing.Cell culture and infection with recombinant adenoviruses
TT cells were obtained from the American Type Culture
Collection (Rockville, MD, USA) and maintained in
Dulbecco’s modified Eagle’s medium (DMEM)/F12C10%
FBS supplemented with 100 units/ml penicillin and 100 mg/ml
streptomycin and were incubated at 37 8C and 5% CO2.
For infection with adenoviral vectors, cells were first
depleted of estrogen for 3 days using phenol red-free
DMEM/F12 containing 5% dextran/charcoal-stripped FBS.
Transduction efficiency of the adenoviral vectors in cell lines
was tested using AdGal. b-galactosidase expression was
detected in 95–100% of TT cells at 48 h after infection
with AdGal at a multiplicity of infection (MOI) of 10www.endocrinology-journals.org
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Therefore, subsequent experiments were performed by
similar amounts (10 or 20 PFU/cell) of recombinant
adenoviral vectors.
The transcriptional activities of ERa or ERb were assayed
using an artificial estrogen-responsive reporter (Ad-3ERE-luc)
or AP1 reporter (Ad-AP1-luc) in a viral vector (Lee et al.
2001). Briefly, 12-well plates of TT cells were infected for 5 h
with 10 PFU/cell Ad-3ERE-Luc or Ad-AP1-Luc with
Ad-ERa or Ad-ERb. Fresh medium containing ethanol
vehicle, 17b-estradiol (E2, 1 nM, Sigma), or ICI 182 780
(100 nM, Tocris, Ellisville, MO, USA), a specific estrogen
antagonist, was added; incubation continued for 24 h; and
luciferase activity was assayed.Detection of ERs expression using immunofluorescence and
western blot analysis
TT cells on glass slides 48 h after infection with adenoviral
vectors were fixed in ice-cold methanol for 10 min and
permeabilized with 0.4% Triton-X 100 in PBS for 20 min on
ice. After blocking with 10% horse serum for 30 min,
specimens were incubated with mouse monoclonal anti-
human ERa or ERb for 1 h at room temperature. After
washing with TBSC0.025% Tween, specimens were incu-
bated with biotinylated horse anti-mouse secondary antibodies
(5 mg/ml, Vector Laboratories) for 30 min. Streptavidin-
fluorescein isothiocyanate (FITC) (1:100, Vector) and
Streptavidin-Texas-Red (1:100, Vector) were used for the
detection of ERa and ERb respectively. Cell images were
analyzed using a Zeiss microscope (Axioskop, Carl Zeiss Inc).
Infected TT Cells in 10 cm culture dishes at a density of 5
!106 cells/dish were washed twice with PBS, and whole cell
lysates were prepared with lysis buffer (25% glycerol, 0.5 M
NaCl, 1.5 mM MgCl2, 20 mM HEPES (pH 7.9), 1 mMTable 1 Summary of clinical and pathologic characteristics of patients w
Sex TNM (staging)
Duration of
follow-up
(years)
Age at
diagnosis
Number
1 M T2N1b M0(IVA) 13 (A) 32
2 M T2N1a M0(III) 7 (A) 35
3 F T2N1a M0(III) 8 (A) 58
4 F T3N0 M0(II) 7 (A) 29
5 M T2N0M0(II) 9 (A) 38
6 F T2N1M1(IVC) 7 (A) 53
7 F T2N1b M0(IVA) 6 (A) 66
8 M T4aN1aM1(IVA) 1 (L) 36
9 F T3N1 M0(III) 2 (L) 55
10 F T2N0M0(II) 4 (A) 69
11 M T2N0M0(II) 1 (L) 63
A, alive; L, lost to follow-up; ND, not done. Normal range: calcitonin, male:!90
according to the percentage of positive cells: K, negative; C, 5–15%; CC, 15–
www.endocrinology-journals.orgphenylmethylsulfonyl fluoride, 0.2 mM EDTA, 25 mM NaF,
and protease inhibitor cocktail tablets (Roche Molecular
Biochemicals)). Equal amounts of protein (10 mg) were
resolved by SDS–PAGE on 10% gel and transferred to
nitrocellulose paper. ERa or ERb was detected using the
antibodies as described above.The effect of ERs on TT cell growth
The effect of ERa or ERb on TT cell growth was measured
with a non-radioactive cell proliferation assay according to the
manufacturer’s protocol (Cell Titer 96 Aqueous Non-
Radioactive Cell Proliferation Assay, Promega). Cells were
seeded onto 96-well plates at a density of 8!103 cells/well
and infected the following day with adenoviral vectors at
different MOIs (10 and 20 PFU/cell). Medium containing
ethanol vehicle, E2 (1 nM), or ICI 182 780 (100 nM) was
replaced at 5 h after infection and every two days thereafter.
Octaplicate wells were assayed for viable cell density at day 8.
Relative density was calculated as absorbance at 490 nm
divided by that of the Ad-E-infected, 0 nM E2-treated cells,
and expressed as a percentage (meanGS.D).Terminal deoxynucleotidyltransferase (TdT)-mediated UTP end
labeling (TUNEL) assay
TT cells were infected with adenoviral vectors (10 PFU/cell),
treated with 1 nM E2 for 6 days, and then washed twice with
PBS and mounted on glass slides. Cells were fixed for 30 min
in 4% paraformaldehyde and permeabilized with buffer
containing 0.1% sodium acetate and 0.4% Triton X-100 for
10 min on ice. After washing with PBS, a modified TUNEL
was performed by the In Situ Cell Death Detection Kit,
Fluorescein (Boehringer Mannheim Co). TUNEL-positiveith medullary thyroid carcinoma
Plasma level Immunohistochemistry
Calcitonin
(pg/ml)
CEA
(ng/ml) ERa ERb Ki67
320 27.1 K K K
156 2.3 C C K
459.6 2.55 CC K K
6.33 0.6 CCC CCC K
ND 360.3 CCC CCC C
ND ND CCC CCC C
75.1 11.3 CC C K
1623 65 C K K
2474 2.34 CCC CCC C
ND ND CC C K
ND 1.88 CCC CCCC K
pg/ml; female:!70 pg/ml; CEA, 0–2.5 ng/ml. Immunohistochemistry score
40%; CCC, 40–60%; CCCC, O60%.
Journal of Endocrinology (2007) 195, 255–263
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was calculated.Statistical analysis
Values are expressed as meanGS.D. Data analysis was performed
by the Statistics Package for Social Sciences (SPSS system for
Windows 12.0, SPSS Inc., Chicago, IL, USA). Differences
between groups were analyzed using Student’s t-test, and
P!0.05 was considered statistically significant.Results
Expression of ERs in human MTC tumor
ERa was detected in 10 out of 11 (90.9%) tumors. Five tumor
samples exhibited higher (50% cells positive) levels of ERa
expression. ERb was absent in three (27.3%) tumors. Eight
tumor sampleswere positive forERb, and fiveof themexhibited
higher (O40% cells positive) levels of ERb positivity. The one
without ERa also did not have ERb expression. Five tumors
with higher ERa expression also had higher ERb expression,
and three of these were also positive for Ki67 positivity. There
was no difference in ERa and ERb expression according to
gender, TNM tumor staging, or survival (Table 1). Positivity for
ERs or Ki67 was not correlated with serum levels of calcitonin
and CEA. We also performed immunohistochemical staining of
ERs in normal human thyroid tissue as a control and found ERb
expression in parafollicular C cells and thyrocytes. ERb
expression was also detected in parafollicular C cells and
thyrocytes surrounding the tumors. However, we did not detect
ERa in normal thyrocytes or parafollicular C cells from either
normal thyroid gland or normal thyroid tissues adjacent to the
tumors (Fig. 1A).Figure 1 Immunohistochemical staining of normal thyroid and
MTC tumor tissues. Four micrometer sections of paraffin-embedded
tumors were subjected to immunohistochemistry to detect calcito-
nin, chromogranin-A, ERa, ERb, and Ki67 using specific antibodies
as described in the Materials and Methods section. Red arrow
indicates positivity. (A) Photographs of representative samples (!
200). (B) Immunohistochemical positivity for ERa, ERb, and Ki67
was scored according to the number of positive cells:K, negative;
C, 5–15%;CC, 15–40%;CCC,
40–60%;CCCC, O60% (!400).Expression of ERs in TT cells infected with adenoviral vectors
First, we examined the presence of ERa or ERb in MTC TT
cells by immunofluorescence staining and western blot
analysis. ERs were not detected in TT cells (data not
shown). Secondly, we infected TT cells with Ad-ERa or
Ad-ERb. Ad-E-infected cells served as a negative control.
The expression of ERa or ERb was detected by immuno-
fluorescence in the nuclei of TT cells infected with Ad-ERa
or Ad-ERb, but not in cells infected with Ad-E (Fig. 2A
and B). The ER expression was detected in 85–95% of TT
cells infected with 10 PFU/cell of adenoviral vectors (Fig. 2A
and B). Then, further experiments were performed by
equivalent amount of adenoviral vectors.Transcriptional activity of ERs delivered by adenoviral vectors
We evaluated whether expression of ERs delivered by
adenoviral vectors activates an estrogen-responsive reporter
gene, by co-infecting Ad-3ERE-Luc into TT cells withJournal of Endocrinology (2007) 195, 255–263Ad-ERa or Ad-ERb. As shown in Fig. 3, ERE reporter
gene activity was not detected with or without E2 in control
Ad-E-infected cells. Infection with Ad-ERa or Ad-ERb
increased reporter activity without ligand, presumably due to
residual estrogen in the medium. E2 (1 nM) addition activated
reporter activity by ten- and fivefold in Ad-ERa- and
Ad-ERb-infected cells respectively. ICI 182 780, an anti-
estrogen treatment, suppressed reporter activities. These
results suggested that expression of ERa or ERb delivered
by adenoviral vectors is functionally active in the EREwww.endocrinology-journals.org
Figure 2 Expression of ERa or ERb in TT cells after infection with Ad-ERa or Ad-ERb.
Forty-eight hours after adenoviral infection, immunofluorescence staining (A and B)
and western blot analysis (C) were performed by mouse monoclonal antibodies as
described in the Materials and Methods section (!630). NV, no virus.
Estrogen receptors in medullary thyroid carcinoma . M A CHO and others 259reporter system and that both ERs act similarly in the classical
ERE-mediated pathway in TT cells.Effect of ERa or ERb on TT cell growth
To investigate whether the introduction of ERa or ERb in
TT cells affects cell growth, we analyzed the proliferation of
TT cells infected with two different doses (10 and 20
PFU/cell) of adenoviral vectors. Ten PFU/cell of Ad-ERa
stimulated TT cell growth without E2 treatment, and thewww.endocrinology-journals.orgtreatment with E2 (1 nM) for 8 days stimulated cell growth
further. With a higher dose (20 PFU/cell) of Ad-ERa,
growth stimulation was observed in the E2 treatment.
Ad-ERb infection resulted in the suppression of TT cell
growth regardless of E2 treatment. Growth suppression was
more prominent with a higher dose (20 PFU/cell) of
Ad-ERb. ICI 182 780 treatment suppressed the growth of
TT cell infected with either Ad-ERa or Ad-ERb, and
growth suppression was more prominent in Ad-ERb than
Ad-ERa infection (Fig. 4). A positive TUNEL reaction wasJournal of Endocrinology (2007) 195, 255–263
Figure 3 Transcriptional activity of ERs transduced by adenoviral
vectors on artificial ERE reporter system. Ad-3ERE-Luc was co-infected
intoTTcellswithAd-ERaorAd-ERbandLuciferaseactivitywasassayed
as described in the Materials and Methods section. Three independent
experiments were normalized to the activity of Ad-E-infected TT cells
treated with ethanol vehicle. Results are plotted as meanGS.D.
V, vehicle (ethanol); E2, E2 (1 nM); ICI, ICI 182 780 (100 nM).
Figure 4 The effect of ERa or ERb expression on T
treated as described in the Materials and Methods s
182 780, cell growth was determined by cell prolif
Methods section. All results are plotted as meanGS.
t-test was performed between values. *P!0.05 wh
Ad-E infection and #P!0.05 when compared with
infection. V, vehicle (ethanol); E2, E2 (1 nM); ICI, IC
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Journal of Endocrinology (2007) 195, 255–263obtained in Ad-ERb infection (19.8%), whereas positivity
was negligible in Ad-ERa-infected (3.2%) or Ad-E-infected
(!1%) cells (Fig. 5).
Effect of ERs on AP1 pathway in TT cells
To investigate the possible mechanisms of different effects of
ERa or ERb expression on TT cell growth, we evaluated a
non-ERE-mediated pathway inTT cells using the AP1 reporter
system (Paech et al. 1997). Co-infection of Ad-AP1-Luc into
TTcellswithAd-ERaor Ad-ERbwas performed.As shown in
Fig. 6, AP1 reporter gene activity was negligible in control
Ad-E-infected cells. Infection with Ad-ERa or Ad-ERb
increased AP1 reporter activity without ligand. After the
addition of E2, AP1 activity was decreased in Ad-ERa-infected
cells, but increased in Ad-ERb-infected cells. ICI 182 780
treatment decreased AP1 activity in both Ad-ERa- or
Ad-ERb-infected cells, but its activity was higher in
Ad-ERb-infected cells than those infected with Ad-ERa.
These results suggest that non-ERE-mediated signals are
distinct in TT cells expressing ERa or ERb and could also
explain the different effects on cellular growth and proliferation.Discussion
Previously, ERb expression has been reported in normal
thyroid parafollicular C cells (Taylor & Al-Azzawi 2000) and
MTC tumor tissues (Blechet et al. 2007). The presence ofT cell growth. Cells were plated, infected, and
ection. After treatment for 8 days with E2 or ICI
eration assay as described in the Materials and
D. for three independent experiments. Student’s
en compared with corresponding condition in
the condition without E2 treatment in Ad-ERa
I 182 780 (100 nM).
www.endocrinology-journals.org
Figure 5 The effect of ERa or ERb on TT cell apoptosis. TT cells were infected with adenoviral
vectors at an MOI of 10 PFU/cell. After 6 days of treatment with E2 (1 nM), TUNEL assays were
performed. Green fluorescence indicates TUNEL labeling (!630).
Estrogen receptors in medullary thyroid carcinoma . M A CHO and others 261mRNA for ERa and ERb has also been demonstrated in the
human MTC tumor tissues (Egawa et al. 2001). However, the
role of each ER expression is not well defined after cancerous
change. In this study, we have shown an appearance of ERa
(10/11) and a loss of ERb expression (3/11) in the human
MTC tissue samples. It has been well demonstrated that
expression of ERb mRNA and protein decreased or
ERa/ERb mRNA ratio increased in tumor versus normal
tissues in many cancers including breast, ovary, prostate,
and colon (Brandenberger et al. 1998, Foley et al. 2000,
Rutherford et al. 2000, Campbell-Thompson et al. 2001,
Roger et al. 2001, Fixemer et al. 2003, Bardin et al. 2004).
Consistent with these reports, appearance of ERa and loss
of ERb in MTC tumor tissue in our study may result in the
increased ratio of ERa/ERb, suggesting a possible role in
tumor growth and progression. Although Ki67, a mitotic
index, was detected in both ERa- and ERb-positive tumors,
its expression did not correlate with ERa and ERb expression
because these three Ki67-positive tumors had similar levels of
both ERa and ERb. In addition, the expression of ERs did
not correlate with cervical lymphadenopathy or distant
metastasis (TNM staging), suggesting other signals (Wang
et al. 1997, Mustafa et al. 2004), besides ERs, are involved in
tumor growth and progression. Of note is that the number of
MTC cases in our study was also limited.
The presence of ERa expression could also open the
possibilityof using anti-estrogenic compounds for the treatmentwww.endocrinology-journals.orgof MTC. In one report, tamoxifen inhibited the growth of
medullary carcinoma DR081 cells in an in vitro culture and
in vivo tumor cell xenograft implants (Weber et al. 1990). In
another report, tamoxifen treatment failed to show clinical or
biochemical improvement of two MTC patients (one man and
one woman) after 1–3 months of therapy (Garcia-Pascual et al.
1993). The presence of ERs was not identified in either of these
reports. It has been suggested that ERb is significantly
up-regulated in tamoxifen-resistant breast cells and could be
involved in tamoxifen resistance (Speirs et al. 1999a,b). Although
ERb was still detected in most ERa-expressing MTC tumor
tissues in our study, tamoxifen could be a potential therapeutic
agent for the treatment of MTC. The effect of this reagent could
be evaluated through therapeutic trial as an adjuvant treatment
in both genders (Garcia-Pascual et al. 1993).
To examine the roles of ERa and ERb in MTC, we used
adenovirus-mediated expression of each ER in MTC TT cells
devoid of both endogenous receptors. We observed that both
ERa andERb expressed byadenoviral vectorwere functional in
TT cells, resulting in the activation of ERE-mediated gene
transcription in a reporter assay. However, we obtained
opposing cellular responses with regard to proliferation and
apoptosis. ERa acted as a growth stimulator with estrogen
addition, whereas ERb suppressed cell growth regardless of
estrogen treatment in this study. We also investigated whether
the different effects of each ER on TT cell growth could be
reversed by ICI 182 780, an anti-estrogen, but ICI 182 780Journal of Endocrinology (2007) 195, 255–263
Figure 6 Effect of ERs transduced by adenoviral vectors on an
artificial AP1 reporter system. Ad-AP1-Luc was co-infected into TT
cells with Ad-ERa or Ad-ERb and Luciferase activity was assayed as
described in the Materials and Methods section. Three independent
experiments were normalized to the activity of Ad-E-infected TT
cells treated with ethanol vehicle. Results are plotted as meanGS.D.
*P!0.01 when compared with the condition with vehicle
treatment in Ad-ERa infection and #P!0.05 when compared with
the condition with vehicle treatment in Ad-ERb infection. V, vehicle
(ethanol); E2, E2 (1 nM); ICI, ICI 182 780 (100 nM).
M A CHO and others . Estrogen receptors in medullary thyroid carcinoma262suppressed the growth of TT cells expressing either ERa or
ERb. Growth suppression was more prominent in Ad-ERb-
infected cells.This result suggests the presence of other pathways
besides the classical ERE-mediated pathway.
The ER has been known to regulate target genes by at least
two major pathways. The classical pathway for ER signaling is
mediated by receptor binding to EREs. This mode of ER action
has been documented for many genes involved in reproduction
as well as genes involved in cellular growth and metabolism
(Jakacka et al. 2001, 2002). In addition to this classical pathwayof
estrogen action, the ER can also alter gene transcription by a
mechanism that does not require direct ER binding to an ERE.
This non-classical pathway affects gene expression from
promoters containing an AP1 site (Paech et al. 1997, Jakacka et
al. 2001, O’Brien et al. 2006). We tested this possibility using
AP1-Luc, the representative non-ERE-mediated reporter
system (Paech et al. 1997). Adenovirus carrying AP1 Luc (Ad-
AP1-luc) was created and co-infected into TT cells with
Ad-ERa or Ad-ERb. The effect of estrogen and anti-estrogen
on AP1-reporter in TT cells was distinct according to ERa or
ERb expression. Estrogen and anti-estrogen treatment sup-
pressed AP1 activity in Ad-ERa-infected cells, whereasJournal of Endocrinology (2007) 195, 255–263alongside Ad-ERb infection, estrogen further stimulated AP1
activity which in turn is suppressed by anti-estrogen. Suppressed
AP1 activity by ICI 182 780 was still higher in ERb than ERa
expression. This result indicates that signals other than the
classical ERE-mediated pathway might regulate genes including
apoptotic factors and negative cell cycle regulators. Genes
responsible for regulating the different actions by ERa or ERb
still remain to be determined in these TT cell models.
A series of studies revealed that the ERb presence confers a
more favorable prognosis and is also associated with low-grade
tumors, low S-phase fraction, negative axillary node status, and a
higher disease-free survival rate (Jarvinen et al. 2000, Omoto et al.
2001). In addition, exogenouslyexpressing ERbnot only inhibits
proliferation and invasion but also induces apoptosis in many
cancer cells (Lazennec et al. 2001, Qiu et al. 2002, Cheng et al.
2004, Paruthiyil et al. 2004). Repression of c-myc, cyclin D1, and
cyclin A gene transcription and increasing the expression of
p21Cip1 and p27Kip1 were demonstrated by ERb expression
(Paruthiyil et al. 2004). These result in a G2 cell cycle arrest. The
activation of caspase-3 has also been demonstrated in ER-nega-
tive prostate cancer cells, in which ERb was reintroduced by
adenoviral vector (Cheng et al. 2004). Although we did not find
an association between ERb expression and tumor behavior in
human MTC tumor samples, an anti-tumor effect of ERb
expression was observed in the TT cell line. These results indicate
a potential anti-neoplastic role of ERb, which is in good
agreement with previous studies (Lazennec et al. 2001, Qiu et al.
2002, Cheng et al. 2004, Paruthiyil et al. 2004), and also suggest
different roles of ERa and ERb in MTC tumor growth. New
therapeutic approaches for MTC might include pharmaceutical
agents to block ER activity and gene therapy by delivery of ERb.
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